Latest Updates
-
Vaastu Tips For Children’s Bedroom: From Study Table Placement To Sleep Direction, Expert Shares Simple Rules -
Aja Ekadashi 2026: 6th Or 7th September? Know The Correct Date, Vrat Katha, Tithi And Rituals -
PCOS Is Getting Younger: Why More Teenagers Are Being Diagnosed Than Ever Before -
National Nutrition Week 2026: What To Eat To How To Eat — Expert Shares 7 Ayurveda Rules For Mindful Nutrition -
Kareena Kapoor's Power Dressing At ‘Daayra’ Trailer Launch: 6 Bollywood Actresses Who Owned The Blazer Trend -
Dahi Handi 2026: Why Govindas Form Human Pyramids And What The Tradition Really Means -
Teachers Day 2026: 7 Things Students Can Teach Their Teachers In Return -
Happy Teacher's Day 2026: 100+ Wishes, Messages, and Captions To Say Thank You -
Teachers’ Day 2026: Dr Sarvepalli Radhakrishnan's Story And Why We Celebrate His Birthday -
New OTT Releases This Week (31 Aug-6 Sept): What To Watch Across Netflix, JioHotstar, Prime Video And SonyLiv
New Drug For Breast Cancer Treatment
A new drug, called Pertuzumab, related to the controversial drug Herceptin, may pave the way for new treatment of breast cancer.
Pertuzumab works in the same way as Herceptin by targeting the HER-2 gene found in 20 per cent of breast cancer patients.
However, the difference between the two lies in the fact that Herceptin blocks a molecular "switch" that promotes cancer growth, while Pertuzumab completely eradicates the possibility of having the switch at all.
This is the first drug to put into effect this sort of modus operandi. And when the scientists used the results of a “phase two" trial of this drug for treating advanced cancer patients, it showed promising results.
It was found that nearly one fourth of the 66 patients reported disappearance or shrinkage of their tumours. Also, the cancer completely vanished in 8 per cent of cases. In fact, a good 25 per cent of patients reported stabilisation of their cancers for at least six months.
It was found that all the patients in the study were at a stage in their illness where their disease was progressing despite treatment with Herceptin and Pertuzumab was administered as an additional therapy.
The scientists conducted their study at Mount Vernon Hospital, London, and announced it at the American Society of Clinical Oncology in Chicago.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.



Click it and Unblock the Notifications